MedTrace Logo

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

NCT06971900 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-05-14

No results posted yet for this study

Summary

A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

Conditions

  • Erythropoietic Protoporphyria (EPP)

Interventions

DRUG

PORT-77

Active oral dose form

DRUG

Placebo

Matching inactive oral dose form

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Portal Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Portal Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-04
Primary Completion
2026-01-01
Completion
2026-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06971900 on ClinicalTrials.gov